Addex Therapeutics Ltd
ADXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -74.9% | 13.4% | -51.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,149.6% | -135.8% | -734.9% | -512.3% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 1,746% | -654.5% | -1,462.6% | -526.4% |
| EPS Diluted | 8.4 | -16.8 | -55.2 | -54 |
| % Growth | 150% | 69.6% | -2.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |